Literature DB >> 1155435

The present status of vaccination against coccidioidomycosis in man.

D Pappagianis, H B Levine.   

Abstract

Vaccines of killed whole cells of Coccidioides immitis have been injected intramuscularly in 97 human subjects to determine the safety and tolerable dose of vaccine and certain immunologic responses. Seventy-eight individuals received the whole killed spherule preparation; 18 received killed mycelial vaccine. The maximum tolerable dose of spherule vaccine was approximately 5 mg. Systemic effects were slight though in two prior coccidioidin reactors a moderate febrile illness and sbustantial antibody production followed vaccination with killed spherules. The vaccines irregularly induced antibody or delayed hypersensitivity to coccidioidin or spherule antigen. Greater antigenic mass perhaps as a soluble preparation may be needed for consistent immunologic stimulation though the spherule vaccine may be protective despite absence of detectable antibody or sensitivity to coccidioidin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1155435     DOI: 10.1093/oxfordjournals.aje.a112131

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  12 in total

1.  Vaccines to prevent systemic mycoses: holy grails meet translational realities.

Authors:  John N Galgiani
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

2.  Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease.

Authors:  George R Thompson; David A Stevens; Karl V Clemons; Josh Fierer; Royce H Johnson; Jane Sykes; George Rutherford; Michael Peterson; John W Taylor; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2014-10-16       Impact factor: 2.574

3.  The cell wall of fungal human pathogens: its possible role in host-parasite relationships.

Authors:  G San-Blas
Journal:  Mycopathologia       Date:  1982-09-17       Impact factor: 2.574

4.  Immunization of mice against coccidioidomycosis with a subcellular vaccine.

Authors:  D Pappagianis; R Hector; H B Levine; M S Collins
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

5.  Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen.

Authors:  R O Abuodeh; L F Shubitz; E Siegel; S Snyder; T Peng; K I Orsborn; E Brummer; D A Stevens; J N Galgiani
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

Review 6.  Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Authors:  Chinh Nguyen; Bridget Marie Barker; Susan Hoover; David E Nix; Neil M Ampel; Jeffrey A Frelinger; Marc J Orbach; John N Galgiani
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 7.  Coccidioidomycosis: host response and vaccine development.

Authors:  Rebecca A Cox; D Mitchell Magee
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Vaccine-induced cellular immune responses differ from innate responses in susceptible and resistant strains of mice infected with Coccidioides posadasii.

Authors:  Lisa F Shubitz; Sharon M Dial; Robert Perrill; Rachael Casement; John N Galgiani
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

9.  Tempest from Tehachapi takes toll or Coccidioides conveyed aloft and afar.

Authors:  D Pappagianis; H Einstein
Journal:  West J Med       Date:  1978-12

Review 10.  Fungal cell wall vaccines: an update.

Authors:  John E Edwards
Journal:  J Med Microbiol       Date:  2012-01-19       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.